BTW, tomorrow is the last day before IASLC World Conference on Lung Cancer (WCLC 2015)........................

I know...

Take care.

This test cost me 10,000 shares but had increase my confidence of (at least) an upward move.... Charts are confirming. I think the traders-players will take it in the 1.27-1.29 range and will get out by Friday 2:00PM

MH,

I am sorry and understand why you are here...

Have a great day.

ET

Thanks for the advice. I might burn though...

Chris, will we have a run to 1.29 then the same drop back to 1.15?

“After working on 17 drug approvals, it is data like this
that continues to energize me. These robust data will be
important in discussions with the FDA regarding
advancing bavituximab’s clinical development in secondline
non-small cell lung cancer,” said Robert Garnick,
PhD, head of regulatory affairs at Peregrine. “We look
forward to working closely with the FDA to identify the
most efficient path toward commercialization for this
promising candidate in this indication where new
therapies are desperately needed.”

Milestone!

If we close 1.18 or better first time in 12 trading days... in a bloody market...

CP, what is the float?

First resistance level tested... New!

IFU I sold...

I got filled at 1.17

1,000,000 shares sold ATM as announced on $PPHM

Entertaining.......

PPHM stock may alert in the next 5 minutes...

Impossible. My 10K sell wouldn't pass at the ask up of the day.

And now the buying pressure...... I'd rather prefer going back to 1.09-1.12 before....

IFU

Being patient and taking decision based on risk/reward basis is doing the job.

You may want to read this:

Thinking, Fast and Slow is a best-selling[1] 2011 book by Nobel Memorial Prize in Economics winner Daniel Kahneman which summarizes research that he conducted over decades, often in collaboration with Amos Tversky.[2][3] It covers all three phases of his career: his early days working on cognitive biases, his work on prospect theory, and his later work on happiness.

The book's central thesis is a dichotomy between two modes of thought: "System 1" is fast, instinctive and emotional; "System 2" is slower, more deliberative, and more logical. The book delineates cognitive biases associated with each type of thinking, starting with Kahneman's own research on loss aversion. From framing choices to people's tendency to substitute an easy-to-answer question for one that is harder, the book highlights several decades of academic research to suggest that people place too much confidence in human judgment.

On an ugly market day, PPHM stands very well.... Why?

And what happen when we touch 1.19 and 1.21...?


Yeah... ClayTrader will offer us a new video telling the next resistance level is 1.31 then september 7-8 occurs and one PR and BOOM...

Too bad for those waiting on the sidelines. OK they can catch up before 3 and 5 and before MD1225 article spreading before going to 12.5 then 30 because we will be bought... But by Who and When?

Stay tune... WookieWookie we are waiting...

1 out 15 stock followed... The only one GREEN

PPHM

Bavi is a placebo

Read...

"It's very Valeant-esque in many ways," Evercore ISI analyst Umer Raffat wrote of the brodalumab deal in an email to clients. "Picking up an abandoned biopharma asset. Also signals Valeant's increased interest in launch-ready assets (and hence, continued 'organic growth'). Recall recent deals like Salix (IBS-D launch), Sprout (Addyi launch) and now this IL-17 ahead of FDA filing."

Good test.

Was able to unlaod easy on the ask 1.17 all or nothing 10K this morning...

We are going up. Up we go.

Fair article. Well balanced.

Tha take home message is forget about AZN, MRK, PFE. They are dangerous to us. VRX is a wonderful fit. kind of silent partner.....

I would sell then 25% for 100 millions and remove the 175,000,000 shares.

Valeant is our buyer.


Valeant Strikes Psoriasis-Drug Pact With AstraZeneca
Amgen had pulled out of collaboration with AstraZeneca, worried over drug’s side-effects

Bio, I thought no one had notice...

This board is sometimes .... bizarre.

Bavituximab in UK

Bavituximab for advanced non-small cell lung cancer – second line in combination with docetaxel

Source agency:
NIHR-HSC
Date of Submission:
22/07/2015
Date of Printing:
30/08/2015

In the UK, lung cancer is the second most common diagnosed cancer after breast cancer, but it is the most common cause of cancer death in the UK, accounting for more than 1 in 5 cancer deaths(5). In England there were 34,889 cases of lung cancer in 2011 (representing 46.6 cases per 100,000 population) (ICD-10 C33-C34)(6). Approximately 87% of lung cancers are NSCLC, and around 70-75% of these are non-squamous(7). Incidence of lung cancer is higher in lower socioeconomic groups, and survival is poorer in these groups compared to higher socioeconomic groups(8). The majority of lung cancers are diagnosed in the later stages of the disease, with 21% presenting with locally and regionally advanced disease (stage IIIB) and 48% presenting with metastases (stage IV)(2). For people presenting with NSCLC stage IV, the 5-year survival rate varies from 2 to 13%(2). Median survival for patients with stage IV NSCLC treated with platinum-based therapy is 8 to 12 months(9,10). Around 25% of patients with advanced NSCLC receive first line chemotherapy(11). Around 30-40% of these patients may subsequently become candidates for second-line therapy (approximately 1,256-1,675 patients in England)(12).

If licensed, bavituximab will offer an additional treatment option for patients with advanced NSCLC who have progressed despite first line therapy, a group who currently have few effective therapies available.

Bavituximab has potential to increase length of survival in this patient group.

Bavituximab Activates CD8+ TILs in a 3D Ex Vivo System of Lung Cancer Patients Derived Tumors With Negative PD-L1 Expression
S. Altiok, M. Mediavilla Valera, J. Kreahling, N. L. Kallinteris, D. Noyes, T. N. Razabdouski, J. Shan, J. Hutchins, K. Menander, S. J. Antonia

Tuesday, September 8, 2015

Bavituximab Activates CD8+ TILs in a 3D Ex Vivo System of Lung Cancer
Patients Derived Tumors With Negative PD-L1 Expression - Soner Altiok,
USA

From 90 to 96 II in the last 27 days

From 31,352,714 to 34,918,502 Total Institutional Shares

+10% or nearly 3.5 millions more in good hands

Step by step....

From 15.68% to 17.34% in less than a month. Bah.... Dead money....

Retail, my dear.

Securities selling at $1.50 to $1.99
$3.00 per share margin requirement
Securities selling at $1.00 to $1.49
200% of market value margin requirement

Just put a short order 10,000@1,18

Curious to see if it fills...

Realist. You are realistic for real.

Every one should look at Hutchins slides.......................

Then spread them........

Then you have major buying......

AZ doing their DD, PPHM cannot hide P2 mess... So having AZ on board is highly positive. THis is the same for MSK.

Data must be compelling... This is enough to bring bac the 2+ days...

PM activity set a close at 1.27

They will let shorts get out so easy???

Hypi, the market is ready to pour more than a billion after wednesday morning.

With a 1.25B MC or 7$/sh everybody will wake up... ATM at 7 is far better than at 1.2

Ciao...

We may have 8 more million shares to cover on panic mode!

Are we in better shape than early June?

Back to those PPS...



Aug 21, 2015 1.09 1.19 1.09 1.14 1,100,800 1.14
Aug 20, 2015 1.12 1.15 1.12 1.12 822,000 1.12
Aug 19, 2015 1.16 1.18 1.11 1.12 613,400 1.12
Aug 18, 2015 1.27 1.29 1.18 1.18 935,400 1.18
Aug 17, 2015 1.19 1.27 1.17 1.26 1,275,100 1.26
Aug 14, 2015 1.16 1.17 1.14 1.16 484,300 1.16
Aug 13, 2015 1.09 1.22 1.09 1.15 950,400 1.15
Aug 12, 2015 1.14 1.14 1.00 1.09 2,040,200 1.09
Aug 11, 2015 1.06 1.15 1.05 1.13 1,564,200 1.13
Aug 10, 2015 1.21 1.23 1.00 1.09 3,894,500 1.09
Aug 7, 2015 1.22 1.23 1.20 1.20 1,043,800 1.20
Aug 6, 2015 1.25 1.26 1.22 1.23 871,100 1.23
Aug 5, 2015 1.25 1.26 1.24 1.25 450,400 1.25
Aug 4, 2015 1.25 1.27 1.24 1.25 599,600 1.25
Aug 3, 2015 1.24 1.26 1.22 1.24 587,100 1.24
Jul 31, 2015 1.25 1.27 1.23 1.23 1,304,000 1.23
Jul 30, 2015 1.26 1.27 1.22 1.25 1,267,600 1.25
Jul 29, 2015 1.30 1.32 1.23 1.25 1,235,400 1.25
Jul 28, 2015 1.25 1.31 1.24 1.28 996,500 1.28
Jul 27, 2015 1.25 1.26 1.22 1.24 928,300 1.24
Jul 24, 2015 1.26 1.29 1.25 1.25 956,400 1.25
Jul 23, 2015 1.27 1.35 1.26 1.29 1,520,000 1.29
Jul 22, 2015 1.25 1.29 1.22 1.26 1,547,600 1.26
Jul 21, 2015 1.31 1.33 1.25 1.27 1,367,800 1.27
Jul 20, 2015 1.37 1.37 1.31 1.32 1,421,100 1.32
Jul 17, 2015 1.32 1.38 1.32 1.35 1,229,100 1.35
Jul 16, 2015 1.33 1.37 1.30 1.32 1,524,700 1.32
Jul 15, 2015 1.33 1.38 1.30 1.31 1,203,500 1.31
Jul 14, 2015 1.32 1.37 1.31 1.35 1,037,700 1.35
Jul 13, 2015 1.29 1.33 1.29 1.32 615,600 1.32
Jul 10, 2015 1.23 1.30 1.23 1.29 669,400 1.29
Jul 9, 2015 1.23 1.24 1.22 1.23 711,100 1.23
Jul 8, 2015 1.25 1.26 1.21 1.23 1,464,100 1.23
Jul 7, 2015 1.29 1.30 1.26 1.27 612,600 1.27
Jul 6, 2015 1.29 1.30 1.26 1.29 1,194,700 1.29
Jul 2, 2015 1.30 1.31 1.29 1.30 543,700 1.30
Jul 1, 2015 1.31 1.36 1.29 1.29 1,019,400 1.29
Jun 30, 2015 1.31 1.32 1.30 1.31 640,400 1.31
Jun 29, 2015 1.34 1.34 1.30 1.30 1,302,900 1.30
Jun 26, 2015 1.37 1.37 1.31 1.34 1,931,300 1.34
Jun 25, 2015 1.39 1.40 1.35 1.36 1,061,000 1.36
Jun 24, 2015 1.37 1.40 1.36 1.36 526,200 1.36
Jun 23, 2015 1.38 1.39 1.37 1.38 971,500 1.38
Jun 22, 2015 1.40 1.40 1.36 1.38 1,233,400 1.38
Jun 19, 2015 1.41 1.41 1.38 1.40 1,016,900 1.40
Jun 18, 2015 1.36 1.42 1.36 1.41 1,095,900 1.41
Jun 17, 2015 1.37 1.39 1.37 1.38 647,500 1.38
Jun 16, 2015 1.40 1.42 1.37 1.37 664,300 1.37
Jun 15, 2015 1.41 1.42 1.40 1.40 706,800 1.40
Jun 12, 2015 1.46 1.47 1.41 1.43 827,900 1.43
Jun 11, 2015 1.46 1.47 1.44 1.45 550,200 1.45
Jun 10, 2015 1.43 1.46 1.41 1.46 1,055,600 1.46
Jun 9, 2015 1.46 1.48 1.43 1.43 849,100 1.43
Jun 8, 2015 1.50 1.50 1.44 1.47 1,356,900 1.47
Jun 5, 2015 1.45 1.49 1.44 1.49 1,675,300 1.49
Jun 4, 2015 1.44 1.48 1.44 1.46 1,080,400 1.46
Jun 3, 2015 1.42 1.48 1.41 1.45 2,252,100 1.45
Jun 2, 2015 1.40 1.44 1.40 1.41 944,700 1.41
Jun 1, 2015 1.45 1.46 1.37 1.41 1,830,900 1.41

What is PPHM today?

Worldwide Patents
4 running or close running trial including a P3 (21 months) for one of the deadliest disease
No debt
68,000,000$
MSK
New AZN collaboration
Avid 40,000,000$ backlog and 52% margin
Part of the new hot I/O

Please feel free to add...